FDA Approves New Sunscreen Ingredient, Enhancing Protection for Consumers
In a significant advancement for sun safety, the U.S. Food and Drug Administration (FDA) has granted approval for bemotrizinol, also known as PARSOL Shield, marking the first new sunscreen ingredient to be added to the market in over two decades. This chemical filter has been a staple in Europe and Asia for years, celebrated for its superior ability to block both UVA and UVB rays, which are known to contribute to skin damage and cancer.
The introduction of bemotrizinol is expected to provide consumers with enhanced protection against harmful ultraviolet rays, effectively closing the existing UVA protection gap. Health and Human Services Secretary Robert F. Kennedy, Jr. emphasized the significance of this approval, noting that it will not only boost competition in the sunscreen market but also increase consumer confidence in the safety and efficacy of sunscreen products.
Bemotrizinol distinguishes itself from older sunscreen filters due to its broad-spectrum protective capabilities and photostability, which means it retains its effectiveness even when exposed to sunlight. Research indicates that it can be used safely at concentrations of up to 6% and is absorbed minimally through the skin, with plasma levels remaining well below FDA safety thresholds.
Mike Davis, MD, Acting Director of the FDA Center for Drug Evaluation and Research, highlighted that this approval is a pivotal step in modernizing the regulatory framework to ensure that American consumers have access to the most effective over-the-counter products available. This innovation aligns with the broader goals outlined in the Make America Health Again strategy, which aims to revitalize the sunscreen market and improve regulatory processes for over-the-counter products.
For dermatologists and skincare experts, the approval of bemotrizinol is a welcome development. Dr. Susan Mayou, a consultant dermatologist in the UK, pointed out that the U.S. market has long lagged behind Europe in terms of advanced UV filters. While existing sunscreens in the U.S. provide adequate protection when applied correctly, newer formulations containing bemotrizinol offer improved stability, robust UVA protection, and aesthetically pleasing textures that make them more comfortable to wear.
Consumers can anticipate the arrival of sunscreens featuring bemotrizinol by the end of 2026, with wider availability likely to follow. This new ingredient promises to lead to lighter formulations that are less likely to leave a white residue on the skin, making sunscreen use more appealing.
As the sunscreen market evolves, it’s essential for consumers to choose products wisely. Experts recommend looking for sunscreens labeled as “broad-spectrum” with a minimum SPF of 30, considering water resistance, and paying attention to personal skin types and preferences. Proper application—using about an ounce for full-body coverage, applying 15 minutes before sun exposure, and reapplying every two hours—is crucial for effective sun protection.
Overall, the FDA’s approval of bemotrizinol represents a significant leap forward in sun safety, providing consumers with access to modern, effective, and scientifically-backed skincare solutions.
